Venetoclax

IDH1 Mutation

Justin Watts, MDSmall moleculePhase 2Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 89/ 100

Competitive context

6 Active assets in the IDH1 Mutation cohort.

Asset / Sponsor	Phase	Rating
ag-120 Massachusetts General Hospital	Phase 2	BB
Azacitidine Shen yang	Phase 2	B
Nivolumab Jason J. Luke, MD	Phase 2	B
Cytosin-Arabinosid Shen yang	Phase 2	CCC
Olutasidenib Timothy Pardee	Phase 2	CCC
Daunorubicin Shen yang	Phase 2	CCC
Pamiparib Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 1/2	CCC

Same molecule, other indications

Venetoclax is also rated in:

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant

BBB

Indicative ·

72 / 100

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant

BB

Indicative ·

70 / 100

myeloid neoplasmDormant

BB

Indicative ·

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.